#United States #New York #Apertura Gene Therapy #TfR1 CapX #ARPA-H THRIVE

Apertura Gene Therapy Joins Forces in Revolutionary Consortium

Apertura Gene Therapy, a pioneering biotechnology firm specializing in advanced adeno-associated virus (AAV) capsids, has announced its active participation in a newly formed consortium. This group has been selected to receive funding from the Advanced Research Projects Agency for Health (ARPA-H) under its THRIVE program, with the specific goal of developing innovative gene therapies targeted at rare childhood diseases.

The consortium is spearheaded by the Broad Institute of MIT and Harvard, focusing on its Center for Therapeutic Genetics. At the heart of their project is Apertura's groundbreaking CNS-targeted AAV capsid, known as TfR1 CapX™, which will facilitate base and prime gene editing initiatives. The inclusion of academic researchers, clinicians, patient advocates, and biotech companies presents an unprecedented collaborative effort aimed at expediting the development of therapeutic solutions for a range of challenging pediatric neurological disorders.

Addressing an Urgent Need

Recent statistics reveal that over three million children globally struggle with developmental and epileptic encephalopathies resulting from mutations across more than 400 distinct genes. The complexities involved make traditional therapeutic strategies untenable, thus showcasing an urgent need for innovative approaches. Andrew Steinsapir, Acting Chief Technology Officer of Apertura and Gene Therapy Program Lead at Deerfield Management, stated, "By collaborating with patient advocacy organizations and pooling resources across multiple programs, the consortium is taking an innovative stance to advance treatments for a variety of neurogenetic disorders."

The TfR1 CapX capsid, which allows for intravenous administration, is meticulously engineered to target the human transferrin receptor 1 (hTfR1). This ability enables it to navigate the challenging blood-brain barrier, providing broad access to both the brain and spinal cord, thus maximizing therapeutic delivery.

Advanced Gene Editing Technology

In this venture, TfR1 CapX will be integrated with state-of-the-art gene editing technologies developed by David Liu, Ph.D., a recognized authority within the Broad Institute. This partnership is designed to leverage cutting-edge science to address conditions that previously faced significant barriers in treatment development.

Notably, the consortium's manufacturing responsibilities will be handled by Viralgen, a leading entity within the contract development and manufacturing organization (CDMO) sector specializing in recombinant AAV gene therapies. Andy Holt, Chief Commercial Officer at Viralgen, expressed optimism regarding their role, asserting their eagerness to support the consortium’s mission of advancing therapies for rare CNS diseases.

A Strategic Commitment

The collaborative initiative underscores Apertura's dedicated resolve to expand the reach of its TfR1 CapX technology within the industry. The company has entered into multiple licensing agreements pertaining to TfR1 CapX programs, with several anticipated to commence clinical trials within the upcoming year, marking significant progress in this vital area of research.

About TfR1 CapX™

TfR1 CapX™ stands at the forefront as a revolutionary capsid designed for intravenous application that successfully crosses the blood-brain barrier. It has garnered validation from numerous for-profit and nonprofit entities, with ongoing discussions for further licensing opportunities. The capsid's clinical readiness has been bolstered by extensive preclinical development efforts that include regulatory interactions and collaborations with various CDMOs.

Remarkably, TfR1 CapX is a proprietary, advanced second-generation capsid boasting enhanced CNS delivery capabilities compared to earlier versions such as Apertura's first-generation capsid, the BI-hTFR1. Research detailing the performance of this earlier capsid has been published in the journal Science, establishing a solid foundational basis for its successors.

About Apertura Gene Therapy

Founded in 2021 and located in New York City, Apertura Gene Therapy is committed to the advancement of genetic medicines and next-generation AAV capsids that directly engage human receptors, aiming to create more effective and tailored gene delivery systems. The company's leading capsid, TfR1 CapX™, harnesses the human transferrin receptor 1, streamlining intravenous delivery to the critical regions of the brain and spinal cord. With a strong clinical history and the potential to address severe neurological and genetic conditions, Apertura’s innovative solutions are gaining traction. The firm is poised for rapid growth, with multiple clinical trials expected to launch in the next twelve months.

For further information, please visit Apertura Gene Therapy or follow them on LinkedIn.